Clinical Trial Detail

NCT ID NCT03213652
Title Ensartinib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With ALK or ROS1 Genomic Alterations (A Pediatric MATCH Treatment Trial)
Recruitment Recruiting
Gender both
Phase Phase II
Variant Requirements Yes
Sponsors National Cancer Institute (NCI)
Indications

non-Hodgkin lymphoma

histiocytosis

Advanced Solid Tumor

neuroblastoma

Therapies

Ensartinib

Age Groups: adult child

Additional content available in CKB BOOST